# A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

> **NCT04777409** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1840 (actual)

## Conditions studied

- Early Alzheimer´s Disease

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT04777409
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-18
- **Primary completion:** 2025-09-15
- **Final completion:** 2026-01-30
- **Target enrollment:** 1840 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777409, "A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04777409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*